AR054593A1 - METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDO - Google Patents

METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDO

Info

Publication number
AR054593A1
AR054593A1 ARP060103274A ARP060103274A AR054593A1 AR 054593 A1 AR054593 A1 AR 054593A1 AR P060103274 A ARP060103274 A AR P060103274A AR P060103274 A ARP060103274 A AR P060103274A AR 054593 A1 AR054593 A1 AR 054593A1
Authority
AR
Argentina
Prior art keywords
prevent
treat
methods
glucosido
pirazol
Prior art date
Application number
ARP060103274A
Other languages
Spanish (es)
Inventor
Frank Himmelsbach
Roland Maier
Peter Eickelmann
Leo Thomas
Edward Leon Barsoumian
Klaus Dugi
Sabine Quispe Bravo
Regine Ritter
Rudiger Streicher
Koichi Fujita
Toshihiro Hatanaka
Nozomu Ishida
Katsumi Maezono
Koji Soshumi
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR054593A1 publication Critical patent/AR054593A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente se refiere a métodos para prevenir o tratar trastornos metabolicos, para mejorar el control glucémico, para prevenir la progresion desde la tolerancia alterada a la glucosa, la resistencia a la insulina y/o desde el síndrome metabolico hasta la diabetes mellitus de tipo 2, para prevenir o tratar las complicaciones de la diabetes mellitus, para reducir el peso, para prevenir o tratar la degeneracion de las células beta pancreáticas, para tratar la hiperinsulinemia y la resistencia a la insulina y la diabetes de tipo 1, en pacientes que lo necesiten, mediante la administracion de una composicion farmacéutica que comprende un pirazol-O-glucosido como se define en la reivindicacion 1, o su profármaco, o su sal farmacéuticamente aceptable.This refers to methods to prevent or treat metabolic disorders, to improve glycemic control, to prevent progression from impaired glucose tolerance, insulin resistance and / or from metabolic syndrome to type 2 diabetes mellitus , to prevent or treat the complications of diabetes mellitus, to reduce weight, to prevent or treat degeneration of pancreatic beta cells, to treat hyperinsulinemia and insulin resistance and type 1 diabetes, in patients who need, by administering a pharmaceutical composition comprising a pyrazole-O-glucoside as defined in claim 1, or its prodrug, or its pharmaceutically acceptable salt.

ARP060103274A 2005-07-28 2006-07-28 METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDO AR054593A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05016390 2005-07-28

Publications (1)

Publication Number Publication Date
AR054593A1 true AR054593A1 (en) 2007-06-27

Family

ID=35427576

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103274A AR054593A1 (en) 2005-07-28 2006-07-28 METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDO

Country Status (18)

Country Link
US (1) US20070072813A1 (en)
EP (1) EP1912656A2 (en)
JP (1) JP2009502875A (en)
KR (1) KR20080043801A (en)
CN (1) CN101222928A (en)
AR (1) AR054593A1 (en)
AU (1) AU2006274834A1 (en)
BR (1) BRPI0614121A2 (en)
CA (1) CA2616702A1 (en)
EA (1) EA200800198A1 (en)
EC (1) ECSP088139A (en)
IL (1) IL188988A0 (en)
NO (1) NO20076346L (en)
PE (1) PE20070402A1 (en)
TW (1) TW200738246A (en)
UY (1) UY29694A1 (en)
WO (1) WO2007014895A2 (en)
ZA (1) ZA200710713B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
CA2621269A1 (en) * 2005-07-22 2007-01-25 Boehringer Ingelheim International Gmbh Processes for preparing pyrazole-o-glycoside derivatives and novel intermediates of said processes
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
UY30082A1 (en) 2006-01-11 2007-08-31 Boehringer Ingelheim Int CRYSTAL FORM OF 1- (1-METHYLETHYL) -4` - ((2-FLUORO-4-METOXIFENIL) METHYL) -5`- METHYL-1H-PIRAZOL-3`-OBD-GLUCOPYRANOSIDE, A METHOD FOR PREPARATION AND USE OF THE SAME TO PREPARE MEDICATIONS
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
NO347644B1 (en) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorphs
US20080020987A1 (en) * 2006-07-20 2008-01-24 Waldemar Pfrengle Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes
EP2061767B1 (en) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
CL2008000133A1 (en) * 2007-01-19 2008-05-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND DERIVED FROM PIRAZOL-O-GLUCOSIDE COMBINED WITH AT LEAST A SECOND THERAPEUTIC AGENT; AND USE OF THE COMPOSITION FOR THE TREATMENT OF MELLITUS DIABETES, CATARATS, NEUROPATHY, MYOCARDIAL INFARTS, AND
WO2008090209A2 (en) * 2007-01-26 2008-07-31 Boehringer Ingelheim International Gmbh Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
UY31290A1 (en) * 2007-08-16 2009-03-31 PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-O-GLUCOSIDO
UY31291A1 (en) * 2007-08-16 2009-03-31 PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-0-GLUCOSIDO
CL2008002427A1 (en) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus.
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
KR20200118243A (en) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
UY32030A (en) * 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
MX2011002558A (en) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Combination therapy for the treatment of diabetes and related conditions.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CN104906582A (en) 2009-02-13 2015-09-16 勃林格殷格翰国际有限公司 Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
JP2012525419A (en) * 2009-04-30 2012-10-22 グラクソスミスクライン エルエルシー Chemical process
CN102482312A (en) 2009-08-26 2012-05-30 赛诺菲 Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
JP5696156B2 (en) 2009-11-02 2015-04-08 ファイザー・インク Dioxa-bicyclo [3.2.1] octane-2,3,4-triol derivative
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
KR20190050871A (en) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 Diabetes therapy
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
KR101985384B1 (en) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264451A (en) * 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
US5274111A (en) * 1992-04-07 1993-12-28 American Home Products Corporation Trifluoromethyl substituted 1H-pyrazoles and derivatives thereof
KR100591585B1 (en) * 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
ATE455785T1 (en) * 2000-11-02 2010-02-15 Ajinomoto Kk NEW PYRAZOLE DERIVATIVES AND AGENTS AGAINST DIABETES CONTAINING THEM
PL209375B1 (en) * 2000-12-28 2011-08-31 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and use thereof in medicines
JP4141258B2 (en) * 2001-02-26 2008-08-27 キッセイ薬品工業株式会社 Glucopyranosyloxypyrazole derivative and its pharmaceutical use
CA2445346C (en) * 2001-04-27 2010-04-06 Ajinomoto Co., Inc. N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
WO2003090783A1 (en) * 2002-04-26 2003-11-06 Ajinomoto Co., Inc. Preventive/remedy for diabetes
US7439232B2 (en) * 2003-04-01 2008-10-21 Taisho Pharmaceutical Co., Ltd. Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
US7375090B2 (en) * 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
CA2539032A1 (en) * 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof
CA2621269A1 (en) * 2005-07-22 2007-01-25 Boehringer Ingelheim International Gmbh Processes for preparing pyrazole-o-glycoside derivatives and novel intermediates of said processes

Also Published As

Publication number Publication date
ECSP088139A (en) 2008-05-30
IL188988A0 (en) 2008-08-07
ZA200710713B (en) 2008-12-31
TW200738246A (en) 2007-10-16
AU2006274834A1 (en) 2007-02-08
PE20070402A1 (en) 2007-04-30
KR20080043801A (en) 2008-05-19
NO20076346L (en) 2008-04-23
UY29694A1 (en) 2007-02-28
AU2006274834A8 (en) 2008-07-17
US20070072813A1 (en) 2007-03-29
BRPI0614121A2 (en) 2011-03-09
EA200800198A1 (en) 2008-08-29
EP1912656A2 (en) 2008-04-23
CN101222928A (en) 2008-07-16
JP2009502875A (en) 2009-01-29
WO2007014895A2 (en) 2007-02-08
WO2007014895A3 (en) 2007-05-10
CA2616702A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
AR054593A1 (en) METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDO
CL2008003153A1 (en) Spiro-condensed compounds, gpr40 agonists: pharmaceutical composition comprising one of the compounds; and the use of the compounds in the preparation of medications for the treatment of diabetes, hyperglycemia, impaired fasting glucose tolerance, among others.
BR112013019744A2 (en) prevention of hypoglycemia in patients with type 2 diabetes mellitus
MX2007012102A (en) Control of blood glucose in diabetes treatment using pulmonarily administered insulin in combination with basal insulin.
BR112013024973A2 (en) prevention of hypoglycemia in patients with type 2 diabetes mellitus
UY31596A1 (en) NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / ACTION PROFILE
CL2008002227A1 (en) Substituted 4 - [(8r) -4-amino-5-oxo-7,8-dihydrorimido [5,4-f] [1,4] oxazepin-6 (5h) -yl] phenyl derivative compounds; its pharmaceutical composition; and use of the compounds in the treatment of type 2 diabetes, particularly useful for treating obesity.
BRPI0718596B8 (en) pharmaceutical compositions for combination therapy with sglt-2 and metformin inhibitors
MY152037A (en) Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
WO2008082602A3 (en) Compounds and pharmaceutical compositions for the treatment of liver disorders
BR112016027469A2 (en) a diabetes treatment composition comprising slow acting insulin analogue conjugate and slow acting insulinotropic peptide conjugate
AR075422A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING LINAGLIPTINE, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME
AR047779A1 (en) COMPOSITIONS AND METHODS TO TREAT DIABETES
UY31291A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-0-GLUCOSIDO
MX2013004699A (en) Pharmaceutical combinations for the treatment of metabolic disorders.
CL2013000716A1 (en) A prodrug or a salt thereof comprising an exendin-conjugate conjugate; preparation procedure of said prodrug; intermediary compounds; pharmaceutical composition that includes it, useful to improve glycemic control in patients with type 2 diabetes.
BR112013029062A2 (en) lixisenatide and metformin for the treatment of type 2 diabetes
MX2012006744A (en) Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases.
BR112014004726A2 (en) pharmaceutical combination for use in glycemic control in type 2 diabetes patients
WO2010129138A3 (en) Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
AR086356A1 (en) PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT OF PATIENTS WHO HAVE TYPE 2 DIABETES
BR112013029269A2 (en) "Pharmaceutical combination for use in improving glucose tolerance in patients with type 2 diabetes and its use."
BR112013004756B1 (en) use of ave0010 for the manufacture of a medication for the treatment of type 2 diabetes mellitus
BRPI0607156A2 (en) compound, pharmaceutical composition, use of the compound, pharmaceutical kit, method for stimulating glucose uptake by muscle cells and / or adipocyte cell and method for stimulating pancreatic secretion
BRPI0607976A2 (en) pharmaceutical composition and use of a composition

Legal Events

Date Code Title Description
FB Suspension of granting procedure